Completed PHASE3 INTERVENTIONAL 3-arm NCT01149174

Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer (EMDA/PRE-TUR)

Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.

Sponsor: University of Rome Tor Vergata

Conditions Superficial Bladder Cancer

Interventions Mitomycin-C 40 mg

Updated 5 times since 2017 Last updated: Oct 3, 2011 Started: Jan 31, 1994 Primary completion: Dec 31, 2003 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Superficial Bladder Cancer and is currently completed. University of Rome Tor Vergata leads this study, which shows 5 recorded versions since 1994 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rome Tor Vergata

Data source: University of Rome Tor Vergata

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy